Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia (PROPLACO-Tel)
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
About this trial
This is an interventional other trial for Hereditary Hemorrhagic Telangiectasia focused on measuring epistaxis, hemorrhage, anticoagulant therapy, antiplatelet therapy
Eligibility Criteria
Inclusion Criteria: Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure) Age > 18 years old Patient able to understand and agree to participate in the study Affiliation to a social security system Exclusion Criteria: Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months Refusal to participate Pregnant woman or who are breast feeding Patients under maintenance of justice, wardship or legal guardianship
Sites / Locations
- CHU d'Angers
- CHU de Bordeaux
- Hôpital Ambroise Paré
- CHU de Caen Normandie
- CHU clermont-ferrandRecruiting
- CHU de Dijon
- CHRU de Lille
- Hospices Civiles de Lyon
- CHU de Montpellier
- CHU de Nancy
- CHU de Nantes
- CHU de Nice
- AP-HP - Hôpital Ténon
- CHU de Poitiers
- CHU de Rennes
- CHRU de Strasbourg
- CHU de Toulouse
Arms of the Study
Arm 1
Other
Cohort study
a single arm, the anticoagulant and/or antiplatelet treatment is not conditioned by the study